Galderma reported that Nemluvio (nemolizumab) maintained improvements in patients with moderate-to-severe atopic dermatitis for up to three years, according to new data presented at EADV 2026.

The company presented the long-term findings as part of its data slate at the congress. Nemolizumab, an IL-31 receptor antagonist, is already approved for atopic dermatitis, and the new analyses address the durability question that clinicians most often raise when moving patients onto a biologic: does the response hold beyond the pivotal trial window?

Galderma says the answer is yes, with sustained improvements observed in patients treated for up to three years. The announcement frames the data as evidence supporting nemolizumab's long-term efficacy and safety profile in this population.

The dataset extends the evidence base for an agent that targets the IL-31 pathway, a mechanism distinct from the IL-4/IL-13 blockers dupilumab and tralokinumab and from oral JAK inhibitors. For dermatologists weighing first-line biologic choices in moderate-to-severe disease, duration-of-response data increasingly factors into that decision alongside speed of onset and magnitude of effect on EASI and pruritus endpoints.

Full details of the presentation — including specific effect sizes, responder rates and safety findings from the extension period — were not available in the initial announcement, and clinicians will want to review the presented posters and late-breaking sessions for the granular results.

Three-year durability data, if confirmed in peer-reviewed publication, would position nemolizumab alongside the longer-established atopic dermatitis biologics in terms of longitudinal evidence. Galderma indicated that the findings will support ongoing discussions with payers and prescribers as the product's real-world footprint grows.